Literature DB >> 9237002

Acute upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin.

S Fukui1, M Coggia, O Goëau-Brissonnière.   

Abstract

Individual hypersensitivity to the vasoconstrictor effects of ergotamine tartrate has been observed even at doses within recommended limits. Hypersensitivity can be induced by concomitant use with other drugs. The best-documented example of drug-induced hypersensitivity to ergotamine tartrate involves antibiotics of the macrolides class. The mechanism underlying this interaction appears to be interference with metabolism of ergotamine tartrate by the liver. In the present report we describe a case of upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin. The fact that the effect was not dose-dependent, disappeared when administration of ampicillin was discontinued, and reappeared when administration of ampicillin was resumed suggests that the underlying mechanism in our patient was immunologic. Since immunologic hypersensitivity to the vasoconstrictor effects of ergotamine tartrate is unpredictable, great caution and close surveillance is advisable when ergotamine tartrate is used in association with other drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237002     DOI: 10.1007/s100169900072

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  3 in total

1.  Ergotamine-induced upper extremity ischemia: a case report.

Authors:  Man Deuk Kim; Gun Lee; Sung Wook Shin
Journal:  Korean J Radiol       Date:  2005 Apr-Jun       Impact factor: 3.500

Review 2.  Clinically significant drug interactions with agents specific for migraine attacks.

Authors:  M J Eadie
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  Ergotism with ischemia in all four extremities: a case report.

Authors:  Seok-Young Jeong; Eui-Seong Lim; Byoung-Soo Shin; Man-Wook Seo; Young-Hyun Kim; Hyo-Sung Kwak; Gyung-Ho Chung; Seul-Ki Jeong
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.